Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals (Nasdaq: MIST) has announced the granting of equity awards to three new employees. The awards consist of 113,000 stock options to purchase company common shares, issued under the company's 2021 Inducement Plan. The options were granted on January 2, 2025, with an exercise price of $2.17 per share, matching the closing price of Milestone's shares on the grant date.
The options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 equal monthly installments. These awards were granted as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously Milestone employees.
Milestone Pharmaceuticals (Nasdaq: MIST) ha annunciato l'assegnazione di premi azionari a tre nuovi dipendenti. I premi consistono in 113.000 opzioni su azioni per acquistare azioni ordinarie della società, emesse nell'ambito del Piano di Incentivazione 2021 dell'azienda. Le opzioni sono state concesse il 2 gennaio 2025, con un prezzo di esercizio di $2,17 per azione, corrispondente al prezzo di chiusura delle azioni di Milestone alla data di assegnazione.
Le opzioni matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il saldo restante che matura in 36 rate mensili uguali. Questi premi sono stati concessi come incentivo per l'impiego in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), specificamente progettata per nuovi assunti che non erano precedentemente dipendenti di Milestone.
Milestone Pharmaceuticals (Nasdaq: MIST) ha anunciado la concesión de premios en equity a tres nuevos empleados. Los premios consisten en 113,000 opciones sobre acciones para comprar acciones comunes de la empresa, emitidas bajo el Plan de Inducción 2021 de la compañía. Las opciones se concedieron el 2 de enero de 2025, con un precio de ejercicio de $2.17 por acción, igualando el precio de cierre de las acciones de Milestone en la fecha de concesión.
Las opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el saldo restante consolidándose en 36 pagos mensuales iguales. Estos premios se otorgaron como material de inducción para el empleo de acuerdo con la Regla de Listado Nasdaq 5635(c)(4), diseñada específicamente para nuevos empleados que no eran anteriormente empleados de Milestone.
밀스톤 제약 (Nasdaq: MIST)는 세 명의 신규 직원에게 주식 보상을 부여했다고 발표했습니다. 이 보상은 회사의 2021 유인 계획에 따라 발행된 113,000개의 주식 옵션으로, 회사의 보통주를 구매할 수 있는 권리를 포함합니다. 옵션은 2025년 1월 2일에 부여되었으며, 행사 가격은 주당 $2.17로, 부여일의 밀스톤 주식 종료 가격에 해당합니다.
옵션은 4년 동안 분할 지급됩니다, 첫 해 이후 25%가 분할 지급되고 나머지 잔액은 36개월의 동일한 월 지급액으로 분할 지급됩니다. 이 상은 밀스톤의 이전 직원이 아닌 신규 채용자를 위한 유인 자료로서 Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Milestone Pharmaceuticals (Nasdaq: MIST) a annoncé l'octroi de récompenses en actions à trois nouveaux employés. Les récompenses consistent en 113 000 options d'achat d'actions pour acquérir des actions ordinaires de l'entreprise, émises dans le cadre du Plan d'Induction 2021 de la société. Les options ont été accordées le 2 janvier 2025, avec un prix d'exercice de 2,17 $ par action, correspondant au prix de clôture des actions de Milestone à la date d'attribution.
Les options seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le solde restant acquis en 36 mensualités égales. Ces récompenses ont été accordées comme matériel d'incitation pour l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4), spécifiquement conçue pour les nouvelles recrues qui n'étaient pas auparavant des employés de Milestone.
Milestone Pharmaceuticals (Nasdaq: MIST) hat die Gewährung von Eigenkapitalprämien an drei neue Mitarbeiter bekannt gegeben. Die Prämien bestehen aus 113.000 Aktienoptionen zum Kauf von Stammaktien des Unternehmens, die im Rahmen des Induktionsplans 2021 der Gesellschaft ausgegeben wurden. Die Optionen wurden am 2. Januar 2025 gewährt, mit einem Ausübungspreis von $2,17 pro Aktie, was dem Schlusskurs der Milestone-Aktien zum Zeitpunkt der Gewährung entspricht.
Die Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25% nach einem Jahr fällig werden und der verbleibende Betrag in 36 gleichen monatlichen Raten fällig wird. Diese Prämien wurden als Anreizmaterial für die Beschäftigung gemäß Nasdaq-Listenregel 5635(c)(4) gewährt und sind speziell für neue Mitarbeiter konzipiert, die zuvor keine Mitarbeiter von Milestone waren.
- Successful attraction of new talent through equity compensation
- Options granted at market price, aligning with shareholder interests
- Potential future dilution of existing shareholders from 113,000 new options
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 113,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires.
The Options have a grant date of January 2, 2025 and an exercise price of
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity award was granted as an inducement material to the employee entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individual’s entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications
kfox@milestonepharma.com
704-803-9295
FAQ
How many stock options did Milestone Pharmaceuticals (MIST) grant on January 2, 2025?
What is the exercise price for MIST's January 2025 inducement stock options?
What is the vesting schedule for MIST's January 2025 inducement grants?
Under which plan were MIST's January 2025 inducement grants issued?
